Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.
“The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period”
The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories. The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.
“Indirect immunofluorescence segment accounted for the highest CAGR”
Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate. The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.
“Cancer segment accounted for the highest CAGR”
Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases. In 2020, the cancer segment accounted for the highest growth rate. Increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer are the major factors driving this segment's growth.
“Hospitals & Diagnostic Centers segment accounted for the highest CAGR”
Based on end user, the immunofluorescence assays market is segmented intopharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations. In 2020, the hospitals & diagnostics centers segment accounted for the highest growth rate. This can be attributed to the rising number of cases for various diseases coupled with the increasing number of hospitals worldwide are the major driving factors for this segment's growth.
“Asia Pacific: The fastest-growing country in the Immunofluorescence assay market”
The Immunofluorescence assay market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the Immunofluorescence assay market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Immunofluorescence assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
“The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period”
The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories. The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.
“Indirect immunofluorescence segment accounted for the highest CAGR”
Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate. The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.
“Cancer segment accounted for the highest CAGR”
Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases. In 2020, the cancer segment accounted for the highest growth rate. Increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer are the major factors driving this segment's growth.
“Hospitals & Diagnostic Centers segment accounted for the highest CAGR”
Based on end user, the immunofluorescence assays market is segmented intopharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations. In 2020, the hospitals & diagnostics centers segment accounted for the highest growth rate. This can be attributed to the rising number of cases for various diseases coupled with the increasing number of hospitals worldwide are the major driving factors for this segment's growth.
“Asia Pacific: The fastest-growing country in the Immunofluorescence assay market”
The Immunofluorescence assay market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America- 50%, Europe- 32%, APAC-10%, RoW- 8%
- Thermo Fisher Scientific, Inc. (US)
- Abcam plc (UK)
- Bio-Rad Laboratories, Inc. (US)
- PerkinElmer Inc. (US)
- Merck KGaA (Germany)
- Werfen Company (Spain)
- Cell Signaling Technology, Inc. (US)
- MEDIPAN GmbH (Germany)
- Sino Biological, Inc. (China)
- Danaher Corporation (US)
- Maravai LifeSciences (US)
- Enzo Biochem, Inc. (US)
- Becton, Dickinson and Company (US)
- Olympus Corporation (Japan)
- Nikon Corporation (Japan)
- Bruker Corporation (US)
- Agilent Technologies (US)
- Zyagen, Inc. (US)
- Cellabs (Australia)
- J. Mitra & Co. Pvt. Ltd. (India)
- Abnova Corporation (Taiwan)
- EpiGentek Group (US)
- Elabscience, Inc. (US)
- AESKU GROUP GmbH (Germany)
- MaxVision Biosciences Inc. (Canada)
This report provides a detailed picture of the Immunofluorescence assay market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Immunofluorescence assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 IMMUNOFLUORESCENCE ASSAYS MARKET
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.3.3 CURRENCY
1.4 STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 IMMUNOFLUORESCENCE ASSAYS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
FIGURE 5 TOP-DOWN APPROACH
2.2.3 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
FIGURE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 8 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2018 VS. 2023 (USD MILLION)
FIGURE 9 IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 11 GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAYS MARKET
4 PREMIUM INSIGHTS
4.1 IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW
FIGURE 12 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE & COUNTRY (2020)
FIGURE 13 INDIRECT IMMUNOFLUORESCENCE SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.3 IMMUNOFLUORESCENCE ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 KEY MARKET DYNAMICS
FIGURE 15 IMMUNOFLUORESCENCE ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of chronic diseases
TABLE 1 INCIDENCE OF CANCER, 2018 VS. 2040
5.2.1.2 Rising R&D and healthcare spending
FIGURE 16 PHARMACEUTICAL R&D EXPENDITURE, BY GEOGRAPHY, 2010–2016
FIGURE 17 GLOBAL CURRENT HEALTH EXPENDITURE PER CAPITA, 2015–2018
5.2.1.3 Growing industry-academia collaboration
5.2.1.4 Increasing government funding for life science research
TABLE 2 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2017-2020)
5.2.1.5 Growing awareness about early disease detection
5.2.2 RESTRAINTS
5.2.2.1 High instrument costs
5.2.3 OPPORTUNITIES
5.2.3.1 High growth opportunities in emerging markets
TABLE 3 DIABETES PREVALENCE IN EMERGING ECONOMIES, 2019 VS. 2030 VS. 2045
5.2.4 CHALLENGES
5.2.4.1 Quality concerns over research antibodies
5.2.4.2 Lack of skilled professionals
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
5.3 COVID-19 IMPACT ON THE IMMUNOFLUORESCENCE ASSAYS MARKET
TABLE 5 IMMUNOFLUORESCENCE ASSAY TESTS APPROVED FOR COVID-19 DIAGNOSTICS
5.4 PRICING ANALYSIS
TABLE 6 IMMUNOFLUORESCENCE ASSAY PRODUCTS, AVERAGE SELLING PRICES
(IN USD)
5.5 VALUE CHAIN ANALYSIS
FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 19 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES
5.7 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
FIGURE 20 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
5.8 PESTLE ANALYSIS
6 IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
6.2 REAGENTS
TABLE 8 IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 9 IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.1 STAINS & DYES
6.2.1.1 Stains and dyes accounted for the largest share of the reagents segment in 2020
TABLE 10 IMMUNOFLUORESCENCE STAINS & DYES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.2 MEDIA & SERA
6.2.2.1 Serum-free media eliminates the risk of contamination by viruses
TABLE 11 IMMUNOFLUORESCENCE MEDIA & SERA MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.3 FIXATIVES
6.2.3.1 Fixative agents are required for the preservation of morphology and the antigenicity of target molecules
TABLE 12 IMMUNOFLUORESCENCE FIXATIVES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.4 BUFFERS
6.2.4.1 Buffers are widely used in drug development applications
TABLE 13 IMMUNOFLUORESCENCE BUFFERS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
6.2.5 PROBES
6.2.5.1 The use of probes in research is rising owing to its versatile and quantitative capabilities
TABLE 14 IMMUNOFLUORESCENCE PROBES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.6 SOLVENTS
6.2.6.1 Organic solvents are widely used in pharmaceutical processes and immunofluorescence assays
TABLE 15 IMMUNOFLUORESCENCE SOLVENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.7 OTHER REAGENTS
TABLE 16 OTHER IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 17 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 18 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.1 MICROSCOPES
6.3.1.1 Technological advancements in microscopy techniques propel segment growth
TABLE 19 IMMUNOFLUORESCENCE MICROSCOPES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.2 IMAGING ANALYSIS SYSTEMS
6.3.2.1 Imaging analysis systems are widely used in diagnostics and clinical research
TABLE 20 IMMUNOFLUORESCENCE IMAGING ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4 ANTIBODIES
TABLE 21 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026(USD MILLION)
TABLE 22 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.1 PRIMARY ANTIBODIES
6.4.1.1 The increasing demand for accurate and reliable antibodies coupled with rising R&D expenditure drives segment growth
TABLE 23 PRIMARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.2 SECONDARY ANTIBODIES
6.4.2.1 The low cost of production and versatility have ensured stable growth in the market for secondary antibodies
TABLE 24 SECONDARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.5 KITS
6.5.1 THE DEMAND FOR COMPLETE SOLUTIONS AMONG END USERS DRIVES THE GROWTH OF THIS SEGMENT
TABLE 25 IMMUNOFLUORESCENCE KITS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
6.6 CONSUMABLES & ACCESSORIES
TABLE 26 IMMUNOFLUORESCENCE CONSUMABLES & ACCESSORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
7 IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 27 GLOBAL IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 28 COMPARISON BETWEEN DIRECT AND INDIRECT IMMUNOFLUORESCENCE TECHNIQUES
7.2 INDIRECT IMMUNOFLUORESCENCE
7.2.1 INDIRECT IMMUNOFLUORESCENCE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2020
TABLE 29 GLOBAL INDIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION/COUNTRY, 2019–2026 (USD MILLION)
7.3 DIRECT IMMUNOFLUORESCENCE
7.3.1 THE HIGH COST ASSOCIATED WITH DIRECT IMMUNOFLUORESCENCE MAY LIMIT THE GROWTH OF THIS MARKET
TABLE 30 GLOBAL DIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE
8.1 INTRODUCTION
TABLE 31 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
8.2 CANCER
8.2.1 CANCER ACCOUNTED FOR THE LARGEST SHARE OF THE DISEASE SEGMENT IN 2020
TABLE 32 CANCER PREVALENCE, BY TYPE (2018)
TABLE 33 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
TABLE 34 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 INFECTIOUS DISEASES
8.3.1 THE RISING PREVALENCE OF INFECTIOUS DISEASES TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE ASSAY TECHNIQUES
TABLE 35 IMMUNOFLUORESCENCE ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 CARDIOVASCULAR DISEASES
8.4.1 THE HIGH INCIDENCE OF CVD TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE IMAGING TECHNIQUES
TABLE 36 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 AUTOIMMUNE DISEASES
8.5.1 THE PREVALENCE OF AUTOIMMUNE DISEASES HAVE INCREASED WORLDWIDE, THUS SUPPORTING THE GROWTH OF THIS SEGMENT
TABLE 37 PREVALENCE OF AIDS
TABLE 38 IMMUNOFLUORESCENCE ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 OTHER DISEASES
TABLE 39 IMMUNOFLUORESCENCE ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
9 IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 40 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026(USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PHARMA & BIOTECH COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE END-USER SEGMENT IN 2020
TABLE 41 IMMUNOFLUORESCENCE ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 GROWING GOVERNMENT INVESTMENTS FOR R&D TO PROPEL MARKET GROWTH
TABLE 42 IMMUNOFLUORESCENCE ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
9.4 HOSPITALS & DIAGNOSTIC CENTERS
9.4.1 THE RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE GROWTH OF THIS SEGMENT
TABLE 43 IMMUNOFLUORESCENCE ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 EMERGING MARKETS ARE EXPECTED TO PROVIDE ROBUST GROWTH OPPORTUNITIES FOR CROS
TABLE 44 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY/REGION, 2019-2026(USD MILLION)
10 IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 45 IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, SNAPSHOT
TABLE 46 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the North American market in terms of market share
TABLE 54 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION)
TABLE 55 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 56 US: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 57 US: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 58 US: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 59 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 60 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 61 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Support from government organizations is driving the growth of the immunofluorescence assays market in Canada
TABLE 62 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 63 CANADA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 64 CANADA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 CANADA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 68 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 69 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 70 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 EUROPE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 76 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany holds the largest share of the European market
TABLE 77 RESEARCH GRANTS PROVIDED IN GERMANY, 2015–2019
TABLE 78 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 79 GERMANY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 GERMANY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 GERMANY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 84 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Growing R&D investments drive the market in the UK
TABLE 85 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 86 UK: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 UK: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 UK: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 90 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 91 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising research activity supports market growth in France
TABLE 92 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 93 FRANCE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 FRANCE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 FRANCE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 98 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Rising life science R&D and favorable funding scenario are key drivers of the Italian market
TABLE 99 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 100 ITALY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 ITALY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 102 ITALY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 105 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Rising prevalence of chronic disease to support the market growth
TABLE 106 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 107 SPAIN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 SPAIN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 SPAIN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 112 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 113 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 114 ROE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 ROE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 ROE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 119 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET SNAPSHOT
TABLE 120 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 121 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 122 APAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 123 APAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 124 APAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 125 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 126 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 127 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Japan is the largest market for immunofluorescence assays
in the APAC
TABLE 128 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 129 JAPAN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 130 JAPAN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 131 JAPAN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 132 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 133 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 134 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 China is the fastest-growing market for immunofluorescence assays
TABLE 135 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 136 CHINA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 137 CHINA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 138 CHINA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 139 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 140 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 141 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing government spending on healthcare to support market growth
TABLE 142 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 143 INDIA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 144 INDIA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 145 INDIA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 146 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 147 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 148 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 149 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 150 ROAPAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 151 ROAPAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 152 ROAPAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 153 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 154 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 155 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 GROWING CONTRACT RESEARCH & MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 156 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 157 LATIN AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 158 LATIN AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 159 LATIN AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 160 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 161 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 162 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INADEQUATE RESEARCH INFRASTRUCTURE TO HAMPER THE MARKET GROWTH IN THE REGION
TABLE 163 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 164 MEA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 165 MEA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 166 MEA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 167 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 168 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 169 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
FIGURE 23 KEY DEVELOPMENTS IN THE IMMUNOFLUORESCENCE ASSAYS MARKET (2017 TO 2020)
11.2 MARKET SHARE ANALYSIS
FIGURE 24 IMMUNOFLUORESCENCE REAGENTS, KITS, ANTIBODIES, AND CONSUMABLE & ACCESSORIES MARKET SHARE, BY KEY PLAYER (2019)
FIGURE 25 IMMUNOFLUORESCENCE INSTRUMENTS MARKET SHARE, BY KEY PLAYER (2019)
11.3 COMPETITIVE SCENARIO
11.3.1 MARKET EVALUATION FRAMEWORK, 2017-2020
11.3.2 PRODUCT LAUNCHES & APPROVALS
TABLE 170 PRODUCT LAUNCHES & APPROVALS
11.3.3 AGREEMENTS & COLLABORATIONS
TABLE 171 AGREEMENTS & COLLABORATIONS
11.3.4 ACQUISITIONS
TABLE 172 ACQUISITIONS
11.3.5 EXPANSIONS
TABLE 173 EXPANSIONS
11.3.6 OTHER DEVELOPMENTS
TABLE 174 OTHER DEVELOPMENTS
11.4 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
11.4.1 VENDOR EXCLUSION CRITERIA
11.4.2 STARS
11.4.3 EMERGING LEADERS
11.4.4 PERVASIVE PLAYERS
11.4.5 PARTICIPANTS
FIGURE 26 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING
11.5 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES
11.5.1 PROGRESSIVE COMPANIES
11.5.2 STARTING BLOCKS
11.5.3 RESPONSIVE COMPANIES
11.5.4 DYNAMIC COMPANIES
FIGURE 27 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES
12 COMPANY PROFILES
(Business overview, Products offered, Recent developments & MnM View)*
12.1 THERMO FISHER SCIENTIFIC, INC.
FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
12.2 ABCAM PLC
FIGURE 29 ABCAM PLC: COMPANY SNAPSHOT (2020)
12.3 BIO-RAD LABORATORIES, INC.
FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)
12.4 PERKINELMER, INC.
FIGURE 31 PERKINELMER: COMPANY SNAPSHOT (2019)
12.5 MERCK KGAA
FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2019)
12.6 WERFEN COMPANY
FIGURE 33 WERFEN COMPANY: COMPANY SNAPSHOT (2019)
12.7 CELL SIGNALING TECHNOLOGY, INC.
12.8 MEDIPAN GMBH
12.9 SINO BIOLOGICAL, INC.
12.10 DANAHER CORPORATION
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
12.11 MARAVAI LIFESCIENCES
FIGURE 35 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2019)
12.12 ENZO BIOCHEM, INC.
FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2019)
12.13 BECTON, DICKINSON AND COMPANY (BD)
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
12.14 OLYMPUS CORPORATION
FIGURE 38 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2020)
12.15 NIKON CORPORATION
FIGURE 39 NIKON CORPORATION: COMPANY SNAPSHOT (2020)
12.16 BRUKER CORPORATION
12.17 AGILENT TECHNOLOGIES
12.18 ZYAGEN, INC.
12.19 CELLABS
12.20 J. MITRA & CO. PVT. LTD.
12.21 ABNOVA CORPORATION
12.22 EPIGENTEK GROUP
12.23 ELABSCIENCE, INC.
12.24 AESKU.GROUP GMBH
12.25 MAXVISION BIOSCIENCES, INC.
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 IMMUNOFLUORESCENCE ASSAYS MARKET
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.3.3 CURRENCY
1.4 STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 IMMUNOFLUORESCENCE ASSAYS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
FIGURE 5 TOP-DOWN APPROACH
2.2.3 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
FIGURE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 8 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2018 VS. 2023 (USD MILLION)
FIGURE 9 IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 11 GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAYS MARKET
4 PREMIUM INSIGHTS
4.1 IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW
FIGURE 12 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE & COUNTRY (2020)
FIGURE 13 INDIRECT IMMUNOFLUORESCENCE SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.3 IMMUNOFLUORESCENCE ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 KEY MARKET DYNAMICS
FIGURE 15 IMMUNOFLUORESCENCE ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of chronic diseases
TABLE 1 INCIDENCE OF CANCER, 2018 VS. 2040
5.2.1.2 Rising R&D and healthcare spending
FIGURE 16 PHARMACEUTICAL R&D EXPENDITURE, BY GEOGRAPHY, 2010–2016
FIGURE 17 GLOBAL CURRENT HEALTH EXPENDITURE PER CAPITA, 2015–2018
5.2.1.3 Growing industry-academia collaboration
5.2.1.4 Increasing government funding for life science research
TABLE 2 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2017-2020)
5.2.1.5 Growing awareness about early disease detection
5.2.2 RESTRAINTS
5.2.2.1 High instrument costs
5.2.3 OPPORTUNITIES
5.2.3.1 High growth opportunities in emerging markets
TABLE 3 DIABETES PREVALENCE IN EMERGING ECONOMIES, 2019 VS. 2030 VS. 2045
5.2.4 CHALLENGES
5.2.4.1 Quality concerns over research antibodies
5.2.4.2 Lack of skilled professionals
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
5.3 COVID-19 IMPACT ON THE IMMUNOFLUORESCENCE ASSAYS MARKET
TABLE 5 IMMUNOFLUORESCENCE ASSAY TESTS APPROVED FOR COVID-19 DIAGNOSTICS
5.4 PRICING ANALYSIS
TABLE 6 IMMUNOFLUORESCENCE ASSAY PRODUCTS, AVERAGE SELLING PRICES
(IN USD)
5.5 VALUE CHAIN ANALYSIS
FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 19 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES
5.7 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
FIGURE 20 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
5.8 PESTLE ANALYSIS
6 IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
6.2 REAGENTS
TABLE 8 IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 9 IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.1 STAINS & DYES
6.2.1.1 Stains and dyes accounted for the largest share of the reagents segment in 2020
TABLE 10 IMMUNOFLUORESCENCE STAINS & DYES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.2 MEDIA & SERA
6.2.2.1 Serum-free media eliminates the risk of contamination by viruses
TABLE 11 IMMUNOFLUORESCENCE MEDIA & SERA MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.3 FIXATIVES
6.2.3.1 Fixative agents are required for the preservation of morphology and the antigenicity of target molecules
TABLE 12 IMMUNOFLUORESCENCE FIXATIVES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.4 BUFFERS
6.2.4.1 Buffers are widely used in drug development applications
TABLE 13 IMMUNOFLUORESCENCE BUFFERS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
6.2.5 PROBES
6.2.5.1 The use of probes in research is rising owing to its versatile and quantitative capabilities
TABLE 14 IMMUNOFLUORESCENCE PROBES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.6 SOLVENTS
6.2.6.1 Organic solvents are widely used in pharmaceutical processes and immunofluorescence assays
TABLE 15 IMMUNOFLUORESCENCE SOLVENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.7 OTHER REAGENTS
TABLE 16 OTHER IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 17 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 18 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.1 MICROSCOPES
6.3.1.1 Technological advancements in microscopy techniques propel segment growth
TABLE 19 IMMUNOFLUORESCENCE MICROSCOPES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.2 IMAGING ANALYSIS SYSTEMS
6.3.2.1 Imaging analysis systems are widely used in diagnostics and clinical research
TABLE 20 IMMUNOFLUORESCENCE IMAGING ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4 ANTIBODIES
TABLE 21 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026(USD MILLION)
TABLE 22 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.1 PRIMARY ANTIBODIES
6.4.1.1 The increasing demand for accurate and reliable antibodies coupled with rising R&D expenditure drives segment growth
TABLE 23 PRIMARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.2 SECONDARY ANTIBODIES
6.4.2.1 The low cost of production and versatility have ensured stable growth in the market for secondary antibodies
TABLE 24 SECONDARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.5 KITS
6.5.1 THE DEMAND FOR COMPLETE SOLUTIONS AMONG END USERS DRIVES THE GROWTH OF THIS SEGMENT
TABLE 25 IMMUNOFLUORESCENCE KITS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
6.6 CONSUMABLES & ACCESSORIES
TABLE 26 IMMUNOFLUORESCENCE CONSUMABLES & ACCESSORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
7 IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 27 GLOBAL IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 28 COMPARISON BETWEEN DIRECT AND INDIRECT IMMUNOFLUORESCENCE TECHNIQUES
7.2 INDIRECT IMMUNOFLUORESCENCE
7.2.1 INDIRECT IMMUNOFLUORESCENCE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2020
TABLE 29 GLOBAL INDIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION/COUNTRY, 2019–2026 (USD MILLION)
7.3 DIRECT IMMUNOFLUORESCENCE
7.3.1 THE HIGH COST ASSOCIATED WITH DIRECT IMMUNOFLUORESCENCE MAY LIMIT THE GROWTH OF THIS MARKET
TABLE 30 GLOBAL DIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE
8.1 INTRODUCTION
TABLE 31 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
8.2 CANCER
8.2.1 CANCER ACCOUNTED FOR THE LARGEST SHARE OF THE DISEASE SEGMENT IN 2020
TABLE 32 CANCER PREVALENCE, BY TYPE (2018)
TABLE 33 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
TABLE 34 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 INFECTIOUS DISEASES
8.3.1 THE RISING PREVALENCE OF INFECTIOUS DISEASES TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE ASSAY TECHNIQUES
TABLE 35 IMMUNOFLUORESCENCE ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 CARDIOVASCULAR DISEASES
8.4.1 THE HIGH INCIDENCE OF CVD TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE IMAGING TECHNIQUES
TABLE 36 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 AUTOIMMUNE DISEASES
8.5.1 THE PREVALENCE OF AUTOIMMUNE DISEASES HAVE INCREASED WORLDWIDE, THUS SUPPORTING THE GROWTH OF THIS SEGMENT
TABLE 37 PREVALENCE OF AIDS
TABLE 38 IMMUNOFLUORESCENCE ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 OTHER DISEASES
TABLE 39 IMMUNOFLUORESCENCE ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
9 IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 40 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026(USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PHARMA & BIOTECH COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE END-USER SEGMENT IN 2020
TABLE 41 IMMUNOFLUORESCENCE ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 GROWING GOVERNMENT INVESTMENTS FOR R&D TO PROPEL MARKET GROWTH
TABLE 42 IMMUNOFLUORESCENCE ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
9.4 HOSPITALS & DIAGNOSTIC CENTERS
9.4.1 THE RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE GROWTH OF THIS SEGMENT
TABLE 43 IMMUNOFLUORESCENCE ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 EMERGING MARKETS ARE EXPECTED TO PROVIDE ROBUST GROWTH OPPORTUNITIES FOR CROS
TABLE 44 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY/REGION, 2019-2026(USD MILLION)
10 IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 45 IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, SNAPSHOT
TABLE 46 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the North American market in terms of market share
TABLE 54 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION)
TABLE 55 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 56 US: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 57 US: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 58 US: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 59 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 60 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 61 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Support from government organizations is driving the growth of the immunofluorescence assays market in Canada
TABLE 62 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 63 CANADA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 64 CANADA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 CANADA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 68 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 69 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 70 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 EUROPE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 76 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany holds the largest share of the European market
TABLE 77 RESEARCH GRANTS PROVIDED IN GERMANY, 2015–2019
TABLE 78 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 79 GERMANY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 GERMANY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 GERMANY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 84 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Growing R&D investments drive the market in the UK
TABLE 85 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 86 UK: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 UK: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 UK: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 90 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 91 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising research activity supports market growth in France
TABLE 92 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 93 FRANCE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 FRANCE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 FRANCE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 98 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Rising life science R&D and favorable funding scenario are key drivers of the Italian market
TABLE 99 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 100 ITALY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 ITALY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 102 ITALY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 105 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Rising prevalence of chronic disease to support the market growth
TABLE 106 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 107 SPAIN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 SPAIN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 SPAIN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 112 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 113 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 114 ROE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 ROE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 ROE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 119 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET SNAPSHOT
TABLE 120 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 121 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 122 APAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 123 APAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 124 APAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 125 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 126 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 127 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Japan is the largest market for immunofluorescence assays
in the APAC
TABLE 128 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 129 JAPAN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 130 JAPAN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 131 JAPAN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 132 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 133 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 134 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 China is the fastest-growing market for immunofluorescence assays
TABLE 135 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 136 CHINA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 137 CHINA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 138 CHINA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 139 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 140 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 141 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing government spending on healthcare to support market growth
TABLE 142 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 143 INDIA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 144 INDIA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 145 INDIA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 146 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 147 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 148 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 149 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 150 ROAPAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 151 ROAPAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 152 ROAPAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 153 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 154 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 155 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 GROWING CONTRACT RESEARCH & MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 156 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 157 LATIN AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 158 LATIN AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 159 LATIN AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 160 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 161 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 162 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INADEQUATE RESEARCH INFRASTRUCTURE TO HAMPER THE MARKET GROWTH IN THE REGION
TABLE 163 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 164 MEA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 165 MEA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 166 MEA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 167 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 168 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
TABLE 169 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
FIGURE 23 KEY DEVELOPMENTS IN THE IMMUNOFLUORESCENCE ASSAYS MARKET (2017 TO 2020)
11.2 MARKET SHARE ANALYSIS
FIGURE 24 IMMUNOFLUORESCENCE REAGENTS, KITS, ANTIBODIES, AND CONSUMABLE & ACCESSORIES MARKET SHARE, BY KEY PLAYER (2019)
FIGURE 25 IMMUNOFLUORESCENCE INSTRUMENTS MARKET SHARE, BY KEY PLAYER (2019)
11.3 COMPETITIVE SCENARIO
11.3.1 MARKET EVALUATION FRAMEWORK, 2017-2020
11.3.2 PRODUCT LAUNCHES & APPROVALS
TABLE 170 PRODUCT LAUNCHES & APPROVALS
11.3.3 AGREEMENTS & COLLABORATIONS
TABLE 171 AGREEMENTS & COLLABORATIONS
11.3.4 ACQUISITIONS
TABLE 172 ACQUISITIONS
11.3.5 EXPANSIONS
TABLE 173 EXPANSIONS
11.3.6 OTHER DEVELOPMENTS
TABLE 174 OTHER DEVELOPMENTS
11.4 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
11.4.1 VENDOR EXCLUSION CRITERIA
11.4.2 STARS
11.4.3 EMERGING LEADERS
11.4.4 PERVASIVE PLAYERS
11.4.5 PARTICIPANTS
FIGURE 26 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING
11.5 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES
11.5.1 PROGRESSIVE COMPANIES
11.5.2 STARTING BLOCKS
11.5.3 RESPONSIVE COMPANIES
11.5.4 DYNAMIC COMPANIES
FIGURE 27 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES
12 COMPANY PROFILES
(Business overview, Products offered, Recent developments & MnM View)*
12.1 THERMO FISHER SCIENTIFIC, INC.
FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
12.2 ABCAM PLC
FIGURE 29 ABCAM PLC: COMPANY SNAPSHOT (2020)
12.3 BIO-RAD LABORATORIES, INC.
FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)
12.4 PERKINELMER, INC.
FIGURE 31 PERKINELMER: COMPANY SNAPSHOT (2019)
12.5 MERCK KGAA
FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2019)
12.6 WERFEN COMPANY
FIGURE 33 WERFEN COMPANY: COMPANY SNAPSHOT (2019)
12.7 CELL SIGNALING TECHNOLOGY, INC.
12.8 MEDIPAN GMBH
12.9 SINO BIOLOGICAL, INC.
12.10 DANAHER CORPORATION
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
12.11 MARAVAI LIFESCIENCES
FIGURE 35 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2019)
12.12 ENZO BIOCHEM, INC.
FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2019)
12.13 BECTON, DICKINSON AND COMPANY (BD)
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
12.14 OLYMPUS CORPORATION
FIGURE 38 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2020)
12.15 NIKON CORPORATION
FIGURE 39 NIKON CORPORATION: COMPANY SNAPSHOT (2020)
12.16 BRUKER CORPORATION
12.17 AGILENT TECHNOLOGIES
12.18 ZYAGEN, INC.
12.19 CELLABS
12.20 J. MITRA & CO. PVT. LTD.
12.21 ABNOVA CORPORATION
12.22 EPIGENTEK GROUP
12.23 ELABSCIENCE, INC.
12.24 AESKU.GROUP GMBH
12.25 MAXVISION BIOSCIENCES, INC.
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
